<Suppliers Price>

Solcitinib

Names

[ CAS No. ]:
1206163-45-2

[ Name ]:
Solcitinib

[Synonym ]:
N-(5-{4-[(3,3-Dimethyl-1-azetidinyl)carbonyl]phenyl}[1,2,4]triazolo[1,5-a]pyridin-2-yl)cyclopropanecarboxamide
UNII-3V7GQ1260K
N-(5-{4-[(3,3-dimethylazetidin-1-yl)carbonyl]phenyl}[1,2,4]triazolo[1,5-a]pyridin-2-yl)cyclopropanecarboxamide
G154578
solcitinibum
GSK2586184A
GLPG0778
Cyclopropanecarboxamide, N-[5-[4-[(3,3-dimethyl-1-azetidinyl)carbonyl]phenyl][1,2,4]triazolo[1,5-a]pyridin-2-yl]-
solcitinib

Biological Activity

[Description]:

Solcitinib is an orally active, competitive, potent, selective JAK1 inhibitor, with an IC50 of 9.8 nM, and 11-, 55- and 23-fold selectivity over JAK2, JAK3 and TYK2, respectively; Solcitinib is used in the research of moderate-to-severe plaque-type psoriasis.

[Related Catalog]:

Research Areas >> Inflammation/Immunology

[Target]

JAK1:9.8 nM (IC50)


[In Vitro]

Solcitinib is an orally active, competitive, potent, selective JAK1 inhibitor, with an IC50 of 9.8 nM, and 11-, 55- and 23-fold selectivity over JAK2, JAK3 and TYK2, respectively. Solcitinib is used in the research of moderate-to-severe plaque-type psoriasis[1].

[References]

[1]. Ludbrook VJ, et al. Investigation of selective JAK1 inhibitor GSK2586184 for the treatment of psoriasis in a randomized placebo-controlled phase IIa study. Br J Dermatol. 2016 May;174(5):985-95.


[Related Small Molecules]

Baricitinib | Upadacitinib | Pacritinib | CYT387 | AZD1480 | Fedratinib(SAR302503,TG101348) | WP1066 | CHZ868 | AT9283 | GLPG0634 | Itacitinib | cerdulatinib | LY2784544 | SB1317 | Peficitinib

Chemical & Physical Properties

[ Density]:
1.4±0.1 g/cm3

[ Molecular Formula ]:
C22H23N5O2

[ Molecular Weight ]:
389.45000

[ Exact Mass ]:
389.18500

[ PSA ]:
79.60000

[ LogP ]:
1.51

[ Index of Refraction ]:
1.723

[ Storage condition ]:
2-8℃